Alnylam Shares Rise 8% On Preliminary Product Revenue Growth

Dow Jones

14 Jan

By Katherine Hamilton

Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%.

The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months.

The Cambridge, Mass.-based company, which specializes in RNAi therapies, said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday.

Alnylam expects those two products to have accrued $1.22 billion during the full year of 2024, a 34% increase from 2023.

Its products Givlaari and Oxlumo brought in a total product revenue of $109 million in the fourth quarter, and $423 million for the full year. That is a roughly 29% increase from 2023.

Alnylam guided for a net product revenue of $2.05 billion to $2.25 billion in 2025. That would be a 31% increase from 2024's number based on the mid-point of the guidance range.

More than half of its product revenue is expected to come from the Onpattro and Amvuttra treatments, which are projected to grow about 36% compared with 2024. The treatments Givlaari and Oxlumo are expected to bring in 15% more revenue, or $450 million to $525 million.

Alnylam said it anticipates delivering non-GAAP operating income profitability in 2025.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 13, 2025 13:47 ET (18:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503531931"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503531931\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503531931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 02:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503531931","market":"other","top_or_hot":-1,"title":"Alnylam Shares Rise 8% On Preliminary Product Revenue Growth","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. \n</p>\n<p>\n  The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months. \n</p>\n<p>\n  The Cambridge, Mass.-based company, which specializes in RNAi therapies, said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday. \n</p>\n<p>\n  Alnylam expects those two products to have accrued $1.22 billion during the full year of 2024, a 34% increase from 2023. \n</p>\n<p>\n  Its products Givlaari and Oxlumo brought in a total product revenue of $109 million in the fourth quarter, and $423 million for the full year. That is a roughly 29% increase from 2023. \n</p>\n<p>\n  Alnylam guided for a net product revenue of $2.05 billion to $2.25 billion in 2025. That would be a 31% increase from 2024's number based on the mid-point of the guidance range. \n</p>\n<p>\n  More than half of its product revenue is expected to come from the Onpattro and Amvuttra treatments, which are projected to grow about 36% compared with 2024. The treatments Givlaari and Oxlumo are expected to bring in 15% more revenue, or $450 million to $525 million. \n</p>\n<p>\n  Alnylam said it anticipates delivering non-GAAP operating income profitability in 2025. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 13:47 ET (18:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Shares Rise 8% On Preliminary Product Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Shares Rise 8% On Preliminary Product Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-14 02:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. \n</p>\n<p>\n  The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months. \n</p>\n<p>\n  The Cambridge, Mass.-based company, which specializes in RNAi therapies, said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday. \n</p>\n<p>\n  Alnylam expects those two products to have accrued $1.22 billion during the full year of 2024, a 34% increase from 2023. \n</p>\n<p>\n  Its products Givlaari and Oxlumo brought in a total product revenue of $109 million in the fourth quarter, and $423 million for the full year. That is a roughly 29% increase from 2023. \n</p>\n<p>\n  Alnylam guided for a net product revenue of $2.05 billion to $2.25 billion in 2025. That would be a 31% increase from 2024's number based on the mid-point of the guidance range. \n</p>\n<p>\n  More than half of its product revenue is expected to come from the Onpattro and Amvuttra treatments, which are projected to grow about 36% compared with 2024. The treatments Givlaari and Oxlumo are expected to bring in 15% more revenue, or $450 million to $525 million. \n</p>\n<p>\n  Alnylam said it anticipates delivering non-GAAP operating income profitability in 2025. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2025 13:47 ET (18:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2503531931","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503531931","pubTimestamp":1736794020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%.The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months.The Cambridge, Mass.-based company, which specializes in RNAi therapies, said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday.Alnylam expects those two products to have accrued $1.22 billion during the full year of 2024, a 34% increase from 2023.Its products Givlaari and Oxlumo brought in a total product revenue of $109 million in the fourth quarter, and $423 million for the full year. That is a roughly 29% increase from 2023.Alnylam guided for a net product revenue of $2.05 billion to $2.25 billion in 2025. That would be a 31% increase from 2024's number based on the mid-point of the guidance range.More than half of its product revenue is expected to come from the Onpattro and Amvuttra","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"Alnylam股价因初步产品收入增长而上涨8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":0.9},"content_text":"By Katherine Hamilton \n\n\n  Alnylam Pharmaceuticals stock advanced after the company said its preliminary 2024 product revenue rose 34%. \n\n\n  The shares rose 8% to $256.87 Monday. They are up 37% over the past 12 months. \n\n\n  The Cambridge, Mass.-based company, which specializes in RNAi therapies, said it made about $343 million in net product revenue from its Onpattro and Amvuttra products in the fourth quarter of 2024, based on preliminary numbers published Sunday. \n\n\n  Alnylam expects those two products to have accrued $1.22 billion during the full year of 2024, a 34% increase from 2023. \n\n\n  Its products Givlaari and Oxlumo brought in a total product revenue of $109 million in the fourth quarter, and $423 million for the full year. That is a roughly 29% increase from 2023. \n\n\n  Alnylam guided for a net product revenue of $2.05 billion to $2.25 billion in 2025. That would be a 31% increase from 2024's number based on the mid-point of the guidance range. \n\n\n  More than half of its product revenue is expected to come from the Onpattro and Amvuttra treatments, which are projected to grow about 36% compared with 2024. The treatments Givlaari and Oxlumo are expected to bring in 15% more revenue, or $450 million to $525 million. \n\n\n  Alnylam said it anticipates delivering non-GAAP operating income profitability in 2025. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 13:47 ET (18:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}